Search

Displaying results 6771 - 6780 of 10000 in total
  1. Drug

    AP5346

    go.drugbank.com/drugs/DB04992
    Investigational

    AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer.

  2. Drug

    C31G

    go.drugbank.com/drugs/DB05398
    Investigational

    in a phase III pivotal clinical trial for the reduction of sexual transmission of human immunodeficiency virus (HIV). … C31G is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment

  3. Drug

    Suvorexant

    go.drugbank.com/drugs/DB09034
    ApprovedInvestigational

    Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

  4. Drug

    Vimseltinib

    go.drugbank.com/drugs/DB17520
    ApprovedInvestigational

    in a lower risk of off-target effects, including hepatotoxicity. … [A265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results

  5. Drug

    Dialyzable leukocyte extract

    go.drugbank.com/drugs/DB16530
    Investigational

    Transferon is comprised of several peptides mixed from human dialyzable leucocyte extracts and acts as an immunomodulator.

  6. Drug

    Phenobarbital

    go.drugbank.com/drugs/DB01174
    ApprovedInvestigational

    A barbituric acid derivative that acts as a nonselective central nervous system depressant.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index
  7. Drug

    Raseglurant

    go.drugbank.com/drugs/DB05070
    Investigational

    ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM). … The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD, migraine and anxiety.

  8. Drug

    Zomepirac

    go.drugbank.com/drugs/DB04828
    ApprovedWithdrawn

    Zomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions.

  9. Drug

    Brodalumab

    go.drugbank.com/drugs/DB11776
    ApprovedInvestigational

    Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.

    Categories: Interleukin-17 Receptor A Antagonist, Interleukin 17 Receptor A Antagonists
  10. Drug

    Diiodohydroxyquinoline

    go.drugbank.com/drugs/DB09115
    Approved

    Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown.

    Mixtures: Alcortin A, Alcortin A